MultiCell Announces Intellectual Property Portfolio of First-in-Class Technologies Crosses Threshold of 50 Issued or Pending Patents


SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB: MCET), a biopharmaceutical company developing first-in-class drugs based on advanced immune system modulation and other proprietary technologies, today announced that its intellectual property portfolio now totals 54 issued or pending patents that cover its novel drug development platform technologies and new drug candidates.

The Company is leveraging its breakthrough technology platforms to develop a new generation of therapeutic candidates which stimulate or suppress the immune system to treat such conditions as multiple sclerosis, diabetes and infectious and viral diseases such as HIV.

“The aggressive expansion of our patent portfolio is central to both our scientific as well as our growth strategies. Achievement of this latest threshold of 54 issued or pending patents is an indication of our commitment to extend MultiCell’s leadership as a developer of the next generation of immune-modulating drug therapies,” said Dr. Stephen Chang, President and Chief Executive Officer of MultiCell. “Through our key drug development platforms, MultiCell is taking a leadership role in creating first-in-class immune-modulation drugs to target extensive unmet medical needs.”

The US Patent and Trademark Office recently published MultiCell’s US patent application (US Patent Application 20060193855) for its novel therapeutic immunoglobulin-peptide molecules which target disease-specific T-cells.

MultiCell also recently announced it has filed a patent that provides a potential new cancer therapy via a method for treating a range of malignant tumors using the Company's unique technologies to manipulate the immune system.

Modulation of the immune system is central to humans’ ability to combat disease. MultiCell’s therapeutic development strategy targets both the innate and adaptive immune systems via platform technologies known as Toll-like receptors and disease-specific T-cell targeting.

MultiCell is leveraging its platform technologies to develop new drug candidates that effectively ward of disease; some by boosting the immune response, such as would be needed in the case of virus infection. Other MultiCell drug candidates are designed to selectively suppress only those immune cells which are the underlying cause of such serious and difficult-to-treat diseases such as multiple sclerosis or type-1 diabetes.

“MultiCell is developing technologies and drug candidates that can be described as the fourth generation of immune system therapeutics,” Dr. Chang added. “They are continuing in the tradition of the immunological research that saved lives with the first vaccines, then progressed to immune suppression therapy, and more recently to multibillion-dollar markets for targeted immune system-based therapies.”

MultiCell is currently focused on three disease targets with products already in the clinic: multiple sclerosis (MS), type-1 diabetes, and influenza.

The Company’s first-in-class therapeutic pipeline includes:

  • MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world.
  • MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheathof nerve cells. MCT-175 successfully ameliorated the disease in animal models.
  • MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models.
  • MCT-465 for the treatment of virus infection. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models.